Claritev (NYSE:CTEV – Get Free Report) has received an average rating of “Moderate Buy” from the nine analysts that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $44.83.
Several research analysts recently commented on the company. Piper Sandler reiterated an “overweight” rating and issued a $73.00 price target on shares of Claritev in a research report on Wednesday, August 12th. Canaccord Genuity Group raised their price objective on Claritev from $37.00 to $43.00 and gave the company a “buy” rating in a research note on Monday, August 10th. Wells Fargo & Company raised their price objective on Claritev from $22.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 12th. Barclays reiterated an “overweight” rating and issued a $40.00 target price (up from $28.00) on shares of Claritev in a report on Thursday, August 20th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Claritev in a research report on Monday, September 21st.
Read Our Latest Research Report on Claritev
Insider Activity
In other Claritev news, CFO Douglas Garis sold 9,025 shares of the firm’s stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $30.59, for a total value of $276,074.75. Following the completion of the sale, the chief financial officer owned 185,416 shares of the company’s stock, valued at $5,671,875.44. This trade represents a 4.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Travis Dalton bought 5,110 shares of the company’s stock in a transaction on Wednesday, November 11th. The shares were acquired at an average price of $29.34 per share, with a total value of $149,927.40. Following the transaction, the chief executive officer directly owned 57,432 shares of the company’s stock, valued at approximately $1,685,054.88. This trade represents a 9.77% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders purchased 211,560 shares of company stock valued at $5,403,172 over the last ninety days. 7.40% of the stock is owned by corporate insiders.
Institutional Trading of Claritev
Several institutional investors and hedge funds have recently made changes to their positions in CTEV. Public Investment Fund bought a new position in shares of Claritev during the 2nd quarter worth $43,703,438. Bank of America Corp DE raised its holdings in shares of Claritev by 146.6% in the first quarter. Bank of America Corp DE now owns 97,795 shares of the company’s stock valued at $1,598,000 after acquiring an additional 58,133 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Claritev by 306.7% in the third quarter. Goldman Sachs Group Inc. now owns 109,901 shares of the company’s stock valued at $2,327,000 after acquiring an additional 82,877 shares in the last quarter. Entropy Technologies LP purchased a new stake in Claritev in the third quarter worth about $265,000. Finally, Marshall Wace LLP lifted its stake in Claritev by 1,569.2% in the third quarter. Marshall Wace LLP now owns 225,890 shares of the company’s stock worth $4,782,000 after acquiring an additional 212,357 shares during the period. 87.15% of the stock is currently owned by institutional investors.
Claritev Price Performance
NYSE CTEV opened at $25.02 on Tuesday. Claritev has a 1-year low of $11.50 and a 1-year high of $55.50. The business has a 50 day simple moving average of $25.92 and a two-hundred day simple moving average of $25.45. The stock has a market capitalization of $424.09 million, a PE ratio of -1.52 and a beta of 1.05.
Claritev (NYSE:CTEV – Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The company reported $1.77 earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.68) by $5.45. The firm had revenue of $268.31 million for the quarter. On average, analysts anticipate that Claritev will post -15.02 EPS for the current fiscal year.
About Claritev
Claritev, formerly known as MultiPlan, provides technology-enabled services intended to help manage healthcare costs and support payment accuracy. Its offerings include access to provider networks, claims and payment solutions, and data analytics for evaluating healthcare costs and utilization. The company serves health plans, self-insured employers, third-party administrators and other participants in the U.S. healthcare system. Its services are designed to help customers identify cost-management opportunities and support more efficient healthcare transactions.
See Also
- Five stocks we like better than Claritev
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Claritev Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Claritev and related companies with MarketBeat.com's FREE daily email newsletter.
